药明生物首席执行官陈智胜在会上透露,分段生产试点政策的推行,为戈芮宁项目上市节省了至少一年到一年半的时间。近日,北海康成(01228.HK)与药明生物(02269.HK)合作开发生产的注射用维拉苷酶β(商品名:戈芮宁)获国家药监局(NMPA)批准上市,用于治疗12岁及以上青少年和成人I型和III型戈谢病患者。这是中国首个也是目前唯一的本土自主开发的戈谢病酶替代疗法药物。戈谢病是一种因溶酶体中葡萄糖...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.